Context: Swiss pharmaceutical company Roche launched India’s first under-the-skin (subcutaneous) immunotherapy drug, Tecentriq SC (atezolizumab), for lung cancer treatment.
About Under-the-Skin Immunotherapy for Lung Cancer:
What it is?
- Under-the-skin immunotherapy refers to a cancer treatment method where immunotherapy drugs are administered through a subcutaneous injection rather than traditional intravenous (IV) infusion.
- Roche’s Tecentriq SC (atezolizumab) is India’s first approved subcutaneous immunotherapy for:
- Adjuvant Non-Small Cell Lung Cancer (NSCLC)
- Metastatic NSCLC
Aim: To provide faster, more patient-friendly, and less invasive cancer treatment while maintaining the same safety and effectiveness as conventional IV immunotherapy.
Key Features:
- Rapid Administration: Treatment can be delivered in nearly 7 minutes compared to long IV infusion sessions lasting several hours.
- Improved Patient Comfort: Reduces repeated hospital stay, treatment fatigue, and physical discomfort associated with intravenous chemotherapy or immunotherapy.
- Efficient Healthcare Delivery: One hospital unit can treat multiple patients in the time previously required for one IV treatment, improving healthcare resource utilization.
Significance:
- Patient-Centric Cancer Care: Helps reduce mental, physical, and logistical burdens for cancer patients and caregivers, especially those traveling long distances for treatment.
- Strengthening Oncology Infrastructure: Faster administration reduces pressure on tertiary hospitals and supports efficient cancer care delivery amid rising lung cancer cases in India.
Relevance in UPSC Exam Syllabus
- GS Paper III – Science & Technology
-
- Biotechnology and medical innovations
- Emerging healthcare technologies
- Pharmaceutical advancements
- GS Paper II – Health
-
- Public healthcare infrastructure
- Access to affordable healthcare
- Non-communicable diseases (NCDs)
